Pharmacological investigations on potential of peroxisome proliferator-activated receptor-gamma agonists in hyperhomocysteinemia-induced vascular dementia in rats

Neuroscience

Volumn 192, Issue , 2011, Pages 322-333

  Sain, H ^a   Sharma, B ^a   Jaggi, A S ^a   Singh, N ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

Morris water maze; Oxidative stress; Pioglitazone; Rosiglitazone; Vascular dementia

Indexed keywords

ACETYLCHOLINESTERASE; DONEPEZIL; GLUTATHIONE; METHIONINE; NITRATE; NITRITE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BRAIN LEVEL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; HYPERHOMOCYSTEINEMIA; LATENT PERIOD; LEARNING DISORDER; LOW DRUG DOSE; MALE; MAZE TEST; MEMORY DISORDER; MULTIINFARCT DEMENTIA; NITRATE BLOOD LEVEL; NITRITE BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; RAT; VASODILATATION;

ANIMALS; DEMENTIA, VASCULAR; DISEASE MODELS, ANIMAL; HYPERHOMOCYSTEINEMIA; HYPOGLYCEMIC AGENTS; MALE; MAZE LEARNING; PPAR GAMMA; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 80052262855     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.07.002     Document Type: Article

References (101)

1. Abahji T.N., Nill L., Ide N., Keller C., Hoffmann U., Weiss N. Acute hyperhomocysteinemia induces microvascular and macrovascular endothelial dysfunction. Arch Med Res 2007, 38:411-416.
2. Arck P., Toth B., Pestka A., Jeschke U. Nuclear receptors of the peroxisome proliferator-activated (PPAR) family in gestational diabetes: from animal models to clinical trials. Biol Reprod 2010, 83:168-176.
3. Atkinson J. Cerebrovascular structure and dementia: new drug targets. Trends Pharmacolol Sci 2001, 22:630-635.
4. Bermúdez V., Finol F., Parra N., Parra M., Pérez A., Peñaranda L., Vílchez D., Rojas J., Arráiz N., Velasco M. PPAR-gamma agonists and their role in type 2 diabetes mellitus management. Am J Ther 2010, 17:274-283.
5. Beutler R.G., Duron O., Kelly B. Reduced glutathion estimation. J Lb Clin Med 1963, 61:82.
6. Beyer A.M., Baumbach G.L., Halabi C.M., Modrick M.L., Lynch C.M., Gerhold T.D., Ghoneim S.M., de Lange W.J., Keen H.L., Tsai Y.S., Maeda N., Sigmund C.D., Faraci F.M. Interference with PPAR-gamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension 2008, 51:867-871.
7. Bregere C., Rebrin I., Sohal R.S. Detection and characterization of in vivo nitration and oxidation of tryptophan residues in proteins. Methods Enzymol 2008, 441:339-349.
8. Brustolin S., Giugliani R., Félix T.M. Genetics of homocysteine metabolism and associated disorders. Braz J Med Biol Res 2010, 43:1-7.
9. Camarasa J., Rodrigo T., Pubill D., Escubedo E. Memantine is a useful drug to prevent the spatial and non-spatial memory deficits induced by methamphetamine in rats. Pharmacol Res 2010, 62:450-456.
10. Chaturvedi R.K., Adhihetty P., Shukla S., Hennessy T., Calingasan N., Yang L., Starkov A., Kiaei M., Cannella M., Sassone J., Ciammola A., Squitieri F., Beal M.F. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet 2009, 18:3048-3065.
11. Cheng D.M., Jiang Y.G., Huang C.Y., Kong H.Y., Pang W., Yang H.P. Polymorphism of MTHFR C677T, serum vitamin levels and cognition in subjects with hyperhomocysteinemia in China. Nutr Neurosci 2010, 13(4):175-182.
12. Cipolla M.J., Bishop N., Vinke R.S., Godfrey J.A. PPAR{gamma} activation prevents hypertensive remodeling of cerebral arteries and improves vascular function in female rats. Stroke 2010, 41:1266-1270.
13. De la Torre J.C. Vascular risk factor detection and control may prevent Alzheimer's disease. Ageing Res Rev 2010, 9:218-225.
14. Diab A., Deng C., Smith J.D., Hussain R.Z., Phanavanh B., Lovett-Racke A.E., Drew P.D., Racke M.K. Peroxisome proliferators activated receptor-γ agonist 15-deoxy-Delta (12, 14)-prostaglandin J (2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002, 168:2508-2515.
15. Dimitrova K.R., Degroot K.W., Pacquing A.M., Suyderhoud J.P., Pirovic E.A., Munro T.J., Wieneke J.A., Myers A.K., Kim Y.D. Estradiol prevents homocysteine-induced endothelial injury in male rats. Cardiovasc Res 2002, 53:589-596.
16. Doupis J., Eleftheriadou I., Kokkinos A., Perrea D., Pavlatos S., Gonis A., Katsilambros N., Tentolouris N. Acute hyperhomocysteinemia impairs endothelium function in subjects with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2010, 118:453-458.
17. Duan S.Z., Usher M.G., Mortensen R.M. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res 2008, 102:283-294.
18. Ekonomou A., Ballard C.G., Pathmanaban O.N., Perry R.H., Perry E.K., Kalaria R.N., Minger S.L. Increased neural progenitors in vascular dementia. Neurobiol Aging 2010, PMID:20138403.
19. Ellman G.L., Courtney K.D., Andres V., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961, 7:88-95.
20. Fatehi-Hassanabad Z., Tasker R.A. Peroxisome proliferator-activated receptors-gamma (PPAR-gamma) activation confers functional neuroprotection in global ischemia. Neurotox Res 2011, 19:462-471.
21. Firbank M.J., Narayan S.K., Saxby B.K., Ford G.A., O'Brien J.T. Homocysteine is associated with hippocampal and white matter atrophy in older subjects with mild hypertension. Int Psychogeriatr 2010, 22:804-811.
22. Geldmacher D.S., Fritsch T., McClendon M.J., Landreth G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol 2011, 68(1):45-50.
23. Gingerich S., Krukoff T.L. Estrogen modulates endothelial and neuronal nitric oxide synthase expression via an estrogen receptors beta-dependent mechanism in hypothalamic slice cultures. Endocrinology 2005, 146:2933-2941.
24. Glatz T., Stöck I., Nguyen-Ngoc M., Gohlke P., Herdegen T., Culman J., Zhao Y. Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischemic brain. J Hypertens 2010, 28:1488-1497.
25. Gold M., Alderton C., Zvartau-Hind M., Egginton S., Saunders A.M., Irizarry M., Craft S., Landreth G., Linnamägi U., Sawchak S. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010, 30(2):131-146.
26. Halvorsen B., Heggen E., Ueland T., Smith C., Sandberg W.J., Damås J.K., Otterdal K., Tonstad S., Aukrust P. Treatment with the PPARgamma agonist rosiglitazone downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome. Eur J Endocrinol 2010, 162:267-273.
27. Hanyu H., Sato T. Alzheimer's disease. Nippon Rinsho 2010, 68:330-334.
28. He L., Zeng H., Li F., Feng J., Liu S., Liu J., Yu J., Mao J., Hong T., Chen A.F., Wang X., Wang G. Homocysteine impairs coronary artery endothelial function by inhibiting tetrahydrobiopterin in patients with hyperhomocysteinemia. Am J Physiol Endocrinol Metab 2010, 299(6):E1061-E1065.
29. Heneka M.T., Landreth G.E. PPARs in the brain. Biochim Biophys Acta 2007, 1771:1031-1045.
30. Hirashima Y., Seshimo S., Fujiki Y., Okabe M., Nishiyama K., Matsumoto M., Kanouchi H., Oka T. Homocysteine and copper induce cellular apoptosis via caspase activation and nuclear translocation of apoptosis-inducing factor in neuronal cell line SH-SY5Y. Neurosci Res 2010, 67:300-306.
31. Ho Y.S., Yu M.S., Yang X.F., So K.F., Yuen W.H., Chang R.C. Neuroprotective effects of polysaccharides from wolfberry, the fruits of Lycium barbarum, against homocysteine-induced toxicity in rat cortical neurons. J Alzheimers Dis 2010, 19:813-827.
32. Hoshino A., Nakamura T., Enomoto S., Kawahito H., Kurata H., Nakahara Y., Ijichi T. Prevalence of coronary artery disease in Japanese patients with cerebral infarction: impact of metabolic syndrome and intracranial large artery atherosclerosis. Circ J 2008, 72:404-408.
33. Hosoi T., Ogawa K., Ozawa K. Homocysteine induces X-box-binding protein 1 splicing in the mice brain. Neurochem Int 2010, 56:216-220.
34. Ishida H., Takizawa M., Ozawa S., Nakamichi Y., Yamaguchi S., Katsuta N.S. Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: possible protection of beta cells from oxidative stress. Metabolism 2004, 53(4):488-494.
35. Jackson S.M., Parhami F., Xi X.P., Berliner J.A., Hsueh W.A., Law R.E., Demer L.L. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 1999, 19:2094-2104.
36. Jain V., Jaggi A.S., Singh N. Ameliorative potential of rosiglitazone in tibial and sural nerve transection-induced painful neuropathy in rats. Pharmacol Res 2009, 59:385-392.
37. Jayesh B.M., Arvind N.P., Chitrang J.T., Balaraman R. Effect of pioglitazone on l-NAME induced hypertension in diabetic rats. Vasc Pharmacol 2005, 43:260-266.
38. Ji H.J., Hu J.F., Wang Y.H., Chen X.Y., Zhou R., Chen N.H. Osthole improves chronic cerebral hypoperfusion induced cognitive deficits and neuronal damage in hippocampus. Eur J Pharmacol 2010, 636:96-101.
39. Kaundal R.K., Sharma S.S. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. Drug News Perspect 2010, 23(4):241-256.
40. Kaur B., Singh N., Jaggi A.S. Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia. Fundam Clin Pharmacol 2009, 23:557-566.
41. Kaur T., Goel R.K., Balakumar P. Effect of rosiglitazone in sodium arsenite-induced experimental vascular endothelial dysfunction. Arch Pharm Res 2010, 33:611-618.
42. Kiaei M. Peroxisome proliferator-activated receptors-gamma in amyotrophic lateral sclerosis and Huntington's disease. PPAR Res 2008, 2008:418765.
43. Kleinhenz J.M., Kleinhenz D.J., You S., Ritzenthaler J.D., Hansen J.M., Archer D.R., Sutliff R.L., Hart C.M. Disruption of endothelial peroxisome proliferator-activated receptors-gamma reduces vascular nitric oxide production. Am J Physiol Heart Circ Physiol 2009, 297:H1647-H1654.
44. Koladiya R.U., Jaggi A.S., Singh N., Sharma B.K. Ameliorative role of atorvastatin and pitavastatin in l-methionine induced vascular dementia in rats. BMC Pharmacol 2008, 8:14.
45. Koladiya R.U., Jaggi A.S., Singh N., Sharma B.K. Beneficial effects of donepezil on vascular endothelial dysfunction-associated dementia induced by l-methionine in rats. J Health Sci 2009, 55:215-225.
46. Krieger-Hinck N., Schumacher U., Müller A., Valentiner U. The effect of the PPAR-gamma agonist rosiglitazone on neuroblastoma SK-N-SH cells in a metastatic xenograft mouse model. Oncol Res 2010, 18:387-393.
47. Kumari R., Willing L.B., Patel S.D., Krady J.K., Zavadoski W.J., Gibbs E.M., Vannucci S.J., Simpson I.A. The PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse. J Cereb Blood Flow Metab 2010, 30:352-360.
48. Landreth G. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. Curr Alzheimer Res 2007, 4:159-164.
49. Landreth G., Jiang Q., Mandrekar S., Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 2008, 5:481-489.
50. Li WL, Liang X, Wang X, Zhang XD, Liu R, Zhang W, Chen HL, Qin XJ, Bai H, Hai CX (in press) Protective effect of the peroxisome proliferator-activated receptors (PPAR)-gamma, ligand rosiglitazone on tert-butyl hydroperoxide-induced QZG cell injury. Exp Toxicol Pathol.
51. Liu H., Yang M., Li G.M., Qiu Y., Zheng J., Du X., Wang J.L., Liu R.W. The MTHFR C677T polymorphism contributes to an increased risk for vascular dementia: a meta-analysis. J Neurol Sci 2010, 294:74-80.
52. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with Folin-phenol reagent. J Biol Chem 1951, 193:265-275.
53. Morris R.G. Development of a water maze producer for studying spatial learning in the rats. J Neurosci Methods 1984, 11:47-60.
54. Nicolakakis N., Aboulkassim T., Ongali B., Lecrux C., Fernandes P., Rosa-Neto P., Tong X.K., Hamel E. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 2008, 28(37):9287-9296.
55. Nilsson K., Gustafson L., Nornholm M., Hultberg B. Plasma homocysteine, apolipoprotein E status and vascular disease in elderly patients with mental illness. Clin Chem Lab Med 2010, 48:129-135.
56. Nishio Y. Endothelial dysfunction in diabetes. Nippon Rinsho 2010, 68:823-826.
57. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animals tissue by thiobarbituraic acid reaction. Anal Biochem 1979, 95:351-358.
58. Packard M.G., La T., Bazan N.G. Effect of intra-striated injections of platelet-activating factor and PAF antagonist BN 52021 on memory. Neurol Learn Mem 1996, 66:176-182.
59. Park Y.J., Jang Y., Kwon Y.H. Protective effect of isoflavones against homocysteine-mediated neuronal degeneration in SH-SY5Y cells. Amino Acids 2010, 39:785-794.
60. Parle M., Singh N. Reversal of memory deficits by atorvastatin and simvastatin in rats. Yakugaku Zasshi 2007, 127:1125-1137.
61. Pasceri V., Wu H.D., Willerson J.T., Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000, 101:235-238.
62. Pathan A.R., Gaikwad A.B., Viswanad B., Ramarao P. Rosiglitazone attenuates the cognitive deficits induced by high fat diet feeding in rats. Eur J Pharmacol 2008, 589(1-3):176-179.
63. Pathan A.R., Viswanad B., Sonkusare S.K., Ramarao P. Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci 2006, 79:2209-2216.
64. Pieper G.M., Langenstroer P., Siebeneich W. Diabetic-induced endothelial dysfunction in rat aorta: role of hydroxyl radicals. Cardiovasc Res 1997, 34:145-156.
65. Polikandriotis J.A., Mazzella L.J., Rupnow H.L., Hart C.M. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 2005, 25:1810-1816.
66. Poredos P., Jug B. The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. Angiology 2007, 58:309-315.
67. Purroy F., Oró M., Quílez A., Sanahuja J., Brieva L., Granés P. Detection of silent peripheral arterial disease in stroke patients with a low ankle-arm index [in Spanish]. Neurologia 2008, 23:10-14.
68. Qiu L.H., Xie X.J., Zhang B.Q. Astragaloside IV improves homocysteine-induced acute phase endothelial dysfunction via antioxidation. Biol Pharm Bull 2010, 33:641-646.
69. Rivera J., Sobey C.G., Walduck A.K., Drummond G.R. Nox isoforms in vascular pathophysiology: insights from transgenic and knockout mouse models. Redox Rep 2010, 15:50-63.
70. Rodionov R.N., Dayoub H., Lynch C.M., Wilson K.M., Stevens J.W., Murry D.J., Kimoto M., Arning E., Bottiglieri T., Cooke J.P., Baumbach G.L., Faraci F.M., Lentz S.R. Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia. Circ Res 2010, 106:551-558.
71. Rodriguez-Rivera J., Denner L., Dineley K.T. Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status. Behav Brain Res 2011, 216(1):255-261.
72. Sarruf D.A., Yu F., Nguyen H.T., Williams D.L., Printz R.L., Niswender K.D., Schwartz M.W. Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology 2009, 150:707-712.
73. Sastry K.V., Moudgal R.P., Mohan J., Tyagi J.S., Rao G.S. Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy. Anal Biochem 2002, 306:79-82.
74. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T (in press) Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging.
75. Schintu N., Frau L., Ibba M., Caboni P., Garau A., Carboni E., Carta A.R. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci 2009, 29:954-963.
76. Schneck M.J. Vascular dementia. Top Stroke Rehabil 2008, 15:22-26.
77. Sen U., Mishra P.K., Tyagi N., Tyagi S.C. Homocysteine to hydrogen Sulfide or hypertension. Cell Biochem Biophys 2010, 57:49-58.
78. Seo W.K., Yong H.S., Koh S.B., Suh S.I., Kim J.H., Yu S.W., Lee J.Y. Correlation of coronary artery atherosclerosis with atherosclerosis of the intracranial cerebral artery and the extracranial carotid artery. Eur Neurol 2008, 59:292-298.
79. Shah D.I., Singh M. Involvement of Rho-kinase in experimental vascular endothelial dysfunction. Mol Cell Biochem 2006, 283:191-199.
80. Sharma B., Singh N. Pitavastatin and 4'-hydroxy-3'-methoxyacetophenone (HMAP) reduce cognitive dysfunction in vascular dementia during experimental diabetes. Curr Neurovasc Res 2010, 7:180-191.
81. Sharma B., Singh N. Attenuation of vascular dementia by sodium butyrate in streptozotocin diabetic rats. Psychopharmacology (Berl) 2011, 215:677-687.
82. Sharma B., Singh N., Singh M., Jaggi A.S. Exploration of HIV protease inhibitor indinavir as a memory restorative agent in experimental dementia. Pharmacol Biochem Behav 2008, 89:535-545.
83. Sharma B., Singh N., Singh M. Modulation of celecoxib and streptozotocin-induced experimental dementia of Alzheimer's disease type by pitavastatin and donepezil. J Psychopharmacol 2008, 22:162-171.
84. Smulders Y.M., Blom H.J. The homocysteine controversy. J Inherit Metab Dis 2011, 34:93-99.
85. Stevenson S.F., Doubal F.N., Shuler K., Wardlaw J.M. A systematic review of dynamic cerebral and peripheral endothelial function in lacunar stroke versus controls. Stroke 2010, 41(6):e434-e442.
86. Szabo C., Modis K. Pathophysiological roles of peroxynitrite in circulatory shock. Shock 2010, 34(Suppl 1):4-14.
87. Thomas D., Michael T.H., Magdalena S., Jhonnes D., Jorg B.S. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IkappaB induction and block of NFkB and INOS activation. J Neurochem 2004, 88:494-501.
88. Tsuchiya K., Akaza I., Yoshimoto T., Hirata Y. Pioglitazone improves endothelial function with increased adiponectin and high-density lipoprotein cholesterol levels in type 2 diabetes. Endocr J 2009, 56(5):691-698.
89. Tyagi N., Givvimani S., Qipshidze N., Kundu S., Kapoor S., Vacek J.C., Tyagi S.C. Hydrogen sulfide mitigates matrix metalloproteinase-9 activity and neurovascular permeability in hyperhomocysteinemic mice. Neurochem Int 2010, 56:301-307.
90. Vanhoutte P.M. Aging and endothelial dysfunction. Eur Heart J 2004, 4:A8-A17.
91. Verrier E., Wang L., Wadham C., Albanese N., Hahn C., Gamble J.R., Chatterjee V.K., Vadas M.A., Xia P. PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase. Circ Res 2004, 94:1515-1522.
92. Villa P., Bosco P., Ferri R., Perri C., Suriano R., Costantini B., Macrì F., Proto C., Cento R.M., Lanzone A. Fasting and post-methionine homocysteine levels in Alzheimer's disease and vascular dementia. Int J Vitam Nutr Res 2009, 79:166-172.
93. Viswanathan A., Rocca W.A., Tzourio C. Vascular risk factors and dementia: how to move forward. Neurology 2009, 72:368-374.
94. Waldstein S.R., Wendell C.R. Neurocognitive function and cardiovascular disease. J Alzheimers Dis 2010, 20:833-842.
95. Yao L., Li K., Zhang L., Yao S., Piao Z., Song L. Influence of the Pro12Ala polymorphism of PPAR-gamma on age at onset and sRAGE levels in Alzheimer's disease. Brain Res 2009, 1291:133-139.
96. Yu J., Zhang Z., Li Z., Feng X., He L., Liu S., Mao J., Wang G., Wang X. Peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease. J Int Med Res 2010, 38:86-94.
97. Zhang Q, Hu W, Meng B, Tang T (in press) PPARgamma agonist rosiglitazone is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats. Neurol Res.
98. Zhang X.M., Huang G.W., Tian Z.H., Ren D.L., Wilson J.X. Folate Deficiency induces neural stem cell apoptosis by increasing homocysteine in vitro. J Clin Biochem Nutr 2009, 45:14-19.
99. Zhao X., Strong R., Zhang J., Sun G., Tsien J.Z., Cui Z., Grotta J.C., Aronowski J. Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia. J Neurosci 2009, 29:6186-6195.
100. Zhou Q., Liu H., Qiao F., Wu Y., Xu J. VEGF deficit is involved in endothelium dysfunction in preeclampsia. J Huazhong Univ Sci Technolog Med Sci 2010, 30:370-374.
101. Zhu X., Smith M.A., Honda K., Aliev G., Moreira P.I., Nunomura A., Casadesus G., Harris P.L., Siedlak S.L., Perry G. Vascular oxidative stress in Alzheimer disease. J Neurol Sci 2007, 257:240-246.